Company Filing History:
Years Active: 2006-2010
Title: Maria Niewöhner: Pioneering Innovations in Pharmacology
Introduction
Maria Niewöhner is a prominent legal representative based in Wermelskirchen, Germany, recognized for her significant contributions to the field of pharmacology through her innovative inventions. With a remarkable portfolio that includes seven patents, Maria has made her mark in the development of compounds aimed at treating various medical disorders.
Latest Patents
Among her latest patented innovations are the 2-phenyl-substituted imidazotriazinones, which serve as phosphodiesterase inhibitors. These compounds, characterized by short, unbranched alkyl radicals in the 9-position, are synthesized through chlorosulphonation and subsequent reaction with amines. Notably, these compounds inhibit cGMP-metabolizing phosphodiesterases and are tailored for use in pharmaceuticals, particularly for the treatment of cardiovascular and cerebrovascular disorders as well as urogenital system disorders, including erectile dysfunction.
Career Highlights
Throughout her career, Maria Niewöhner has collaborated with esteemed organizations including Bayer Healthcare Aktiengesellschaft and Bayer Aktiengesellschaft. Her work within these respected institutions has been pivotal in advancing the development of innovative pharmaceutical solutions.
Collaborations
In her journey, Maria has worked alongside notable colleagues such as Karl-Heinz Schlemmer and Jörg Keldenich, enhancing her research and development initiatives through collaborative efforts. This teamwork has been instrumental in tackling complex health issues through innovative chemical solutions.
Conclusion
Maria Niewöhner exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions not only demonstrate her expertise but also reflect her commitment to improving health outcomes through her groundbreaking inventions and collaborations. Her ongoing work continues to inspire future generations of inventors in the field of pharmacology.